360 related articles for article (PubMed ID: 17719062)
1. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition.
Douat-Casassus C; Borbulevych O; Tarbe M; Gervois N; Jotereau F; Baker BM; Quideau S
J Med Chem; 2010 Oct; 53(19):7061-6. PubMed ID: 20806940
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes.
Sliz P; Michielin O; Cerottini JC; Luescher I; Romero P; Karplus M; Wiley DC
J Immunol; 2001 Sep; 167(6):3276-84. PubMed ID: 11544315
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides.
Madura F; Rizkallah PJ; Holland CJ; Fuller A; Bulek A; Godkin AJ; Schauenburg AJ; Cole DK; Sewell AK
Eur J Immunol; 2015 Feb; 45(2):584-91. PubMed ID: 25471691
[TBL] [Abstract][Full Text] [Related]
5.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
6. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
Wang Z; Turner R; Baker BM; Biddison WE
J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
[TBL] [Abstract][Full Text] [Related]
7. TCR-induced alteration of primary MHC peptide anchor residue.
Madura F; Rizkallah PJ; Legut M; Holland CJ; Fuller A; Bulek A; Schauenburg AJ; Trimby A; Hopkins JR; Wells SA; Godkin A; Miles JJ; Sami M; Li Y; Liddy N; Jakobsen BK; Loveridge EJ; Cole DK; Sewell AK
Eur J Immunol; 2019 Jul; 49(7):1052-1066. PubMed ID: 31091334
[TBL] [Abstract][Full Text] [Related]
8. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F
J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813
[TBL] [Abstract][Full Text] [Related]
9. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
10. How an alloreactive T-cell receptor achieves peptide and MHC specificity.
Wang Y; Singh NK; Spear TT; Hellman LM; Piepenbrink KH; McMahan RH; Rosen HR; Vander Kooi CW; Nishimura MI; Baker BM
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4792-E4801. PubMed ID: 28572406
[TBL] [Abstract][Full Text] [Related]
11. Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.
Hoppes R; Oostvogels R; Luimstra JJ; Wals K; Toebes M; Bies L; Ekkebus R; Rijal P; Celie PH; Huang JH; Emmelot ME; Spaapen RM; Lokhorst H; Schumacher TN; Mutis T; Rodenko B; Ovaa H
J Immunol; 2014 Nov; 193(10):4803-13. PubMed ID: 25311806
[TBL] [Abstract][Full Text] [Related]
12. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.
Denkberg G; Cohen CJ; Lev A; Chames P; Hoogenboom HR; Reiter Y
Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9421-6. PubMed ID: 12093904
[TBL] [Abstract][Full Text] [Related]
13. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
Denkberg G; Klechevsky E; Reiter Y
J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
[TBL] [Abstract][Full Text] [Related]
14. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
Chen JL; Stewart-Jones G; Bossi G; Lissin NM; Wooldridge L; Choi EM; Held G; Dunbar PR; Esnouf RM; Sami M; Boulter JM; Rizkallah P; Renner C; Sewell A; van der Merwe PA; Jakobsen BK; Griffiths G; Jones EY; Cerundolo V
J Exp Med; 2005 Apr; 201(8):1243-55. PubMed ID: 15837811
[TBL] [Abstract][Full Text] [Related]
15. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
16. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
17. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
18. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
[TBL] [Abstract][Full Text] [Related]
19. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
van Elsas A; van der Burg SH; van der Minne CE; Borghi M; Mourer JS; Melief CJ; Schrier PI
Eur J Immunol; 1996 Aug; 26(8):1683-9. PubMed ID: 8765006
[TBL] [Abstract][Full Text] [Related]
20. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
Douat-Casassus C; Marchand-Geneste N; Diez E; Gervois N; Jotereau F; Quideau S
J Med Chem; 2007 Apr; 50(7):1598-609. PubMed ID: 17328535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
